

**Avapritinib in unresectable or metastatic PDGFRA D842V-mutant  
gastrointestinal stromal tumours: long-term efficacy and safety  
data from the NAVIGATOR phase 1 trial**

**Robin L. Jones <sup>a,\*</sup>, César Serrano <sup>b</sup>, Margaret von Mehren <sup>c</sup>, Suzanne George <sup>d</sup>,  
Michael C. Heinrich <sup>e</sup>, Yoon-Koo Kang <sup>f</sup>, Patrick Schöffski <sup>g</sup>,  
Philippe A. Cassier <sup>h</sup>, Olivier Mir <sup>i</sup>, Sant P. Chawla <sup>j</sup>, Ferry A.L.M. Eskens <sup>k</sup>,  
Piotr Rutkowski <sup>l</sup>, William D. Tap <sup>m</sup>, Teresa Zhou <sup>n</sup>, Maria Roche <sup>n</sup>,  
Sebastian Bauer <sup>o</sup>**

## Appendices

**Table A1. Previous TKI exposure at baseline**

	<i>PDGFRA</i> D842V population ( <i>n</i> = 56)	Safety population ( <i>N</i> = 250)
<b>Prior lines of TKI therapy, median (range)</b>	1 (0–6)	3 (0–11)
<b>Prior lines of TKI therapy, n (%)</b>		
0	11 (20)	11 (4)
1	21 (38)	65 (26)
2	10 (18)	34 (14)
3	6 (11)	44 (18)
≥4	8 (14)	96 (38)

*PDGFRA*, platelet-derived growth factor receptor A; TKI, tyrosine kinase inhibitor.

**Table A2. Treatment-related adverse events in  $\geq 20\%$  of the *PDGFRA* D842V and safety populations**

<b>Preferred term, n (%)</b>	<b><i>PDGFRA</i> D842V population (n = 56)</b>	<b>Safety population (N = 250)</b>
<b>Nausea</b>	33 (59)	148 (59)
<b>Fatigue</b>	31 (55)	135 (54)
<b>Periorbital oedema</b>	26 (46)	109 (44)
<b>Anaemia</b>	32 (57)	103 (41)
<b>Diarrhoea</b>	30 (54)	96 (38)
<b>Vomiting</b>	17 (30)	86 (34)
<b>Increased lacrimation</b>	17 (30)	81 (32)
<b>Memory impairment</b>	23 (41)	80 (32)
<b>Decreased appetite</b>	16 (29)	76 (30)
<b>Peripheral oedema</b>	18 (32)	68 (27)
<b>Hair colour changes</b>	16 (29)	61 (24)
<b>Face oedema</b>	13 (23)	56 (22)
<b>Increased blood bilirubin</b>	15 (27)	49 (20)
<b>Dysgeusia</b>	13 (23)	47 (19)
<b>Neutropenia</b>	14 (25)	29 (12)

PDGFRA, platelet-derived growth factor receptor A.

**Table A3. Any-cause adverse events occurring in  $\geq 20\%$  of patients in the *PDGFRA* D842V population receiving  $< 300$  mg and 300/400 mg starting doses**

Preferred term, n (%)	<i>PDGFRA</i> D842V population (n=56)	
	300/400 mg dose (n = 38)	$< 300$ mg dose (n = 17)
Nausea	28 (74)	9 (53)
Anaemia	26 (68)	11 (65)
Diarrhoea	25 (66)	11 (65)
Fatigue	22 (58)	13 (76)
Memory impairment	18 (47)	5 (29)
Periorbital oedema	17 (45)	10 (59)
Decreased appetite	15 (39)	7 (41)
Increased lacrimation	13 (34)	8 (47)
Peripheral oedema	12 (32)	9 (53)
Vomiting	12 (32)	8 (47)
Abdominal pain	12 (32)	6 (35)
Hypokalaemia	12 (32)	2 (12)
Increased blood bilirubin	12 (32)	3 (18)
Neutropenia	11 (29)	3 (18)
Face oedema	11 (29)	2 (12)
Dizziness	10 (26)	5 (29)
Headache	10 (26)	2 (12)
Hair colour changes	9 (24)	7 (41)
Dyspepsia	9 (24)	4 (24)
AST increase	9 (24)	2 (12)
Hypomagnesemia	9 (24)	2 (12)
URTI	9 (24)	2 (12)
Weight decrease	8 (21)	6 (35)

<b>Dysgeusia</b>	8 (21)	4 (24)
<b>Hypophosphatemia</b>	8 (21)	3 (18)
<b>Constipation</b>	7 (18)	5 (29)
<b>Insomnia</b>	6 (16)	4 (24)
<b>Back pain</b>	6 (16)	4 (24)
<b>Rash</b>	5 (13)	5 (29)
<b>Increased blood creatinine</b>	5 (13)	5 (29)
<b>Influenza-like illness</b>	3 (8)	4 (24)
<b>Gastroenteritis</b>	2 (5)	4 (24)

---

AST, aspartate aminotransferase; PDGFRA, platelet-derived growth factor receptor A; URTI, upper respiratory tract infection.

**Table A4. Any-cause adverse events of special interest in the *PDGFRA* D842V and safety populations**

Adverse event, n (%)	<i>PDGFRA</i> D842V population (n = 56)		Safety population (N = 250)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
<b>Cognitive effects<sup>a</sup></b>	32 (57)	1 (2)	115 (46)	12 (5)
Memory impairment	23 (41)	0	81 (32)	2 (<1)
Confusional state	8 (14)	0	17 (7)	4 (2)
Cognitive disorder	7 (13)	1 (2)	28 (11)	3 (1)
Encephalopathy	1 (2)	0	5 (2)	4 (2)
<b>Intracranial bleeding<sup>a</sup></b>	3 (5)	3 (5)	7 (3)	4 (2)
Intracranial haemorrhage	2 (4)	2 (4)	3 (1)	2 (<1)
Cerebral haemorrhage	1 (2)	1 (2)	1 (<1)	1 (<1)
Subdural haematoma	0	0	3 (1)	1 (<1)

PDGFRA, platelet-derived growth factor receptor A.

<sup>a</sup>Combined term

**Table A5. Deaths in the *PDGFRA* D842V population due to adverse events**

<b>Event, n (%)</b>	<b><i>PDGFRA</i> D842V population (n = 56)</b>
<b>Schizophrenia</b>	1 (2) <sup>a</sup>
<b>Disease progression</b>	3 (5)
<b>General physical health deterioration</b>	2 (4)
<b>Cardiac failure</b>	1 (2)
<b>Hepatic failure</b>	1 (2)
<b>Sepsis</b>	1 (2)

<sup>a</sup>Considered treatment-related.